SEC Form 4 · accession 0001209191-17-059145
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Nov 1, 2017
Accepted (ET)
Nov 3, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2017 | M | 4,000 | $5.5004 | A | 19,977 | D | |
| Common StockF2 | Nov 1, 2017 | S | 1,628 | $144.436 | D | 18,349 | D | |
| Common StockF3 | Nov 1, 2017 | S | 1,272 | $145.3852 | D | 17,077 | D | |
| Common StockF4 | Nov 1, 2017 | S | 1,100 | $146.1364 | D | 15,977 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $5.5004 | Nov 1, 2017 | M | 4,000 | D | — | Jan 16, 2023 | Common Stock | 4,000 | 83,151 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- F2The range of prices for the transaction reported on this line was $144.00 to $144.85. The average weighted price was $144.4360. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range of prices for the transaction reported on this line was $145.00 to $145.75. The average weighted price was $145.3852. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range of prices for the transaction reported on this line was $146.00 to $146.75. The average weighted price was $146.1364. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.